Bone marrow transplantation in the setting of incompatibility between donor ABO antigens and the recipient immune system (major ABO incompatibility) is associated with specific immunohaematological complications. 1 These include acute and delayed haemolysis and delayed onset of donor erythropoiesis. Pure red cell aplasia (PRCA) has been reported to occur in about 15% of HLA-matched major ABO-incompatible pairs. 2 Most cases are felt to be due to the persistence of high-titre host antidonor isohaemagglutinins inhibiting donor erythropoiesis. A role for cell-mediated immune mechanisms has been suggested, where titres are low or absent. 3 We report a case of PRCA following a major ABOincompatible BMT, where the aplasia persisted after the withdrawal of cyclosporin employed for graft-versus-hostdisease prophylaxis. On the basis of persistent mixed chimaerism and minimal isohaemagglutinin titres, cyclosporin was re-introduced in order to treat a presumed Tcell-mediated inhibition of donor erythropoiesis. Erythroid engraftment rapidly ensued and was promptly followed by the switch to a complete donor chimeric state.
A 40-year-old woman was diagnosed with chronic myeloid leukaemia in first chronic phase in March 2001. She proceeded to sibling allogeneic bone marrow transplant using a HLA-matched brother as the donor in November 2001. Donor and recipient were CMV negative. There was a major ABO incompatibility between the donor (A Rh þ ve) and recipient (O Rh Àve). The anti-A isohaemagglutinin titres prior to transplant were 1:64 (IgG) and 1:64 (IgM). The conditioning regimen consisted of busulphan 4 mg/kg p.o. in divided doses daily for 4 days (total dose 16 mg/kg) and cyclophosphamide 60 mg/kg i.v. once daily for 2 days (total dose 120 mg/kg). The total number of mononuclear cells infused was 1.95 Â 10 8 /kg and the CD34 þ cell count was 2.29 Â 10 6 /kg. The cells were infused after red cell depletion, using the COBE 2991 blood cell processor.
Short-course methotrexate and cyclosporin were used for prophylaxis against graft-versus-host disease. Engraftment for neutrophils (40.5 Â 10 9 /l) and platelets (4100 Â 10 9 /l) both took place on day 21. Erythroid engraftment, however, was delayed and the patient remained transfusion-dependent, requiring approximately 4 U of red cells each month. No acute or chronic graft-versus-host disease was seen and the cyclosporin was tapered from day 155 and stopped on day 239.
A bone marrow aspirate on day 106 revealed erythroid aplasia. FISH analysis using dual-labelled ABL and BCR probes was negative for the t(9;22) translocation. Throughout this period, there was no evidence of blood loss. Haemolytic screens were carried out on days 93 and 226. The reticulocyte count on day 226 was 0.4%, the direct antiglobulin test was repeatedly negative and haptoglobins were in the normal range. Erythropoietin levels were elevated at 275 and 565, respectively (normal range -6-25 units). Serology for parvovirus was IgG þ ve and IgM Àve. On day 197, no donor erythropoiesis was yet evident, although assessment of peripheral blood nucleated cell chimeric status using short-tandem repeat profiling by a fluorescent PCR-based technique indicated a predominantly donor profile (see Figure 1 ). 4 On day 295, the patient was still Group O Rh -ve by forward typing with no reduction in transfusion requirements. The anti-A isohaemagglutinin titres were 1:4 (IgG) and undetectable (IgM). A bone marrow biopsy confirmed persistent erythroid hypoplasia. Profuse growth of BMderived BFU-e colonies was seen in culture medium containing erythropoietin. It should be noted, however, that growth was not assessed in the context of either a reduced concentration of patient serum (10%) or autologous T lymphocytes. Although FISH analysis of bone marrow aspirate with a dual-labelled XY probe confirmed complete donor chimerism (XX 0, XY 100), the more sensitive PCR-based technique indicated 99% donor cells in a mixed chimaeric profile. Cyclosporin (5 mg/kg) was introduced on day 295 at a haemoglobin concentration of 6.9 g/dl. On day 302, the reticulocyte count was 1.2%. This increased to 2.1% on day 316. Standard serological testing of the blood group revealed a mixed field reaction from day 316 until day 332. By day 339, the patient had converted to donor erythropoiesis by blood group and to full donor chimerism by molecular analysis of both total nucleated marrow cells and BFU-e colonies. Aspirate morphology revealed trilineage haemopoiesis. The cyclosporin was slowly tapered from day 371 and stopped on day 445. No red cell transfusions were required subsequent to the reintroduction of cyclosporin.
The initial management of delayed erythropoiesis is the regular transfusion of red cell concentrates while awaiting engraftment. Prolonged PRCA, however, requires treatment to prevent transfusion-associated complications, primarily iron overload. Numerous therapeutic approaches have been reported. Plasmapheresis, rituximab and the rapid withdrawal of immunosuppression to deliberately induce a graft-versus-plasma cell effect have each been successfully employed in cases where persistent host isohaemagglutinins have been present. [5] [6] [7] Erythropoietin has proved of benefit not only in the induction of delayed donor erythroid engraftment, but also in establishing erythropoiesis when the donor ABO group is already present and isohaemagglutinins absent. 3, 8 More radically, PRCA has responded to donor lymphocyte infusions (DLI), used either as part of a routine relapse prophylaxis protocol or in the context of late graft failure.
Importantly, several reported cases of PRCA have been characterised by low or absent isohaemagglutinin titres, suggesting a role for cell-mediated immune mechanisms. 3 The inhibition of erythropoiesis may relate to alloreactive immunocompetent host T-cell clones. The use of antithymocyte globulin (ATG) in the presence of low isohaemagglutinin titres led to the rapid resolution of PRCA in an ABO-mismatched transplant, supporting the potential role of T cells in BMT-associated PRCA. 11 In vitro erythroid colony studies documented evidence for T-cell-mediated suppression of erythropoiesis in PRCA, which occurred after chemotherapy for Hodgkin's lymphoma. 12 The aplasia responded to a combination of cyclosporin and erythropoietin.
Cyclosporin may have played a role in the resolution of this case of PRCA. Molecular chimaerism studies confirmed the presence of low-level host haematopoiesis on days þ 197 and þ 295. Although lineage-specific chimaerism was not performed, a role for host alloreactive T cells is supported by the response to a specific inhibitor of T-cell function, that is, cyclosporin. Additionally, IgG antibody titres at the time of introduction of cyclosporin were 1:4, a level below the threshold at which other authors have noted the onset of donor erythropoiesis. 13 The rational choice of therapy for BMT-associated PRCA in the setting of major ABO incompatibility may benefit from knowledge of chimeric status as well as the residual titre of host antidonor isohaemagglutinins. The use of ATG was considered but, in view of the need for inpatient treatment and high-dose corticosteroids, cyclosporin was felt to be preferable. We conclude that cyclosporin may have a role in the treatment of BMT-associated PRCA in the context of absent or low-titre host antidonor isohaemagglutinins. 
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